


Biopharma must play a significant role to help reduce health disparities. From drug development to medication adherence, companies in our sector are uniquely positioned to have an impact on addressing many of the root causes of health inequities in the US healthcare system by incorporating large-scale, targeted initiatives into their R&D and commercial strategy. It's not only our moral obligation to do so as an industry: it also has transformative potential by broadening the patient populations served.

Root Causes of Health Inequity in the US¹

- Limited Medical Knowledge** - Women and non-white populations are disproportionately underrepresented in clinical trials.
- Technology** - Digital technologies have made it easier manage conditions, but underrepresented populations have reduced access.
- Bias in Clinical Decision Making** - Unconscious biases among physicians exist because of race, ethnicity or socioeconomic factors.
- Language** - At least 350 different languages are spoken in US homes, and more than 65 million people in the US have limited English proficiency.
- Social Determinants of Health (SDOH)** - Factors like housing, food and nutrition, transportation and employment have been shown to lead to disparities.

Why Biopharma Should Play a Role in Reducing Health Disparities

There is a business case for biopharma to address it¹



Significant Consequences of Not Addressing These Issues

These Inequities Lead to Challenges in²:

- Preventative Care
- Diagnosis
- Treatment Options
- Treatment Access
- Treatment Adherence

The Consequences are Significant¹

According to an analysis of several high-cost diseases, health inequities cost the US health system about **\$320B a year.**

If health equity isn't addressed, the cost of health inequities could top **\$1T by 2040.**

The Industry Recognizes the Importance and is Responding

Healthcare Executives Recognize the Importance³

93% believe that health equity initiatives are important

89% agree that such initiatives are part of their core business strategy

50% say they have a health equity plan in place

How Initiatives are Being Incorporated

Deliver a patient experience with tailored services that empower patients by driving health literacy and address the barriers driving health disparity.

Incorporate health equity into brand patient services programs across affordability, access, education, training and health coaching.

Measure and articulate value from patient services programs and their impact on the social determinants of health, disparities and barriers to health equity.

Pursue partnerships with solution providers, health systems, payers, employers and broader communities to take a multi-pronged approach.

1. Deloitte. 2. Oliver Wyman. 3. Accenture. 4. Ernest and Young.